Strategic Partnerships Potential collaboration with Gates Foundation, NIH VRC, CEPI, and public pharma partners suggests opportunities to co-develop or license vaccine and therapeutic platforms, especially in infectious disease programs that align with liposomal delivery and MRSA or TB vaccine candidates.

Vaccine Access Growth Recent CEPI partnership and a focus on improving vaccine access indicate a sales angle around distribution partnerships, manufacturing scale-up in Kigali and potential US biotech partnerships to expand mRNA vaccine delivery and supply chain capabilities.

Liposomal Platform Liposomal drug delivery capability presents cross sell potential for other infectious diseases and oncology programs, offering improved biodistribution and therapeutic index which can be pitched to pharma pipelines seeking enhanced safety and efficacy.

Regional Manufacturing Founded manufacturing and trials capabilities in Kigali alongside labs in Boston and San Francisco open doors for regional manufacturing collaborations, contract development and manufacturing opportunities, and tech transfer deals for cost-efficient production.

Funding Momentum Recent $1.5M financing and strong private backing, with revenue in the low-to-mid single digits, signals readiness for pilot partnerships, grant-funded programs, and entry into early-stage clinical collaborations with larger partners seeking innovative infectious disease solutions.